Connor, Clark & Lunn Investment Management (CC&L)’s 4D Molecular Therapeutics FDMT Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio FDMT Stock Details FDMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-65,354	Closed	-$364K	–	1477
2024 Q4	$364K	Buy	65,354 +38,031	+139%	+$298K	﹤0.01%	1223
2024 Q3	$295K	Buy	+27,323	New	+$453K	﹤0.01%	1244
2023 Q3	–	Sell	-21,824	Closed	-$394K	–	1417
2023 Q2	$394K	Sell	21,824 -26,975	-55%	-$497K	﹤0.01%	1047
2023 Q1	$839K	Buy	48,799 +601	+1%	+$11.7K	﹤0.01%	760
2022 Q4	$1.07M	Buy	+48,198	New	+$744K	0.01%	685

Other funds holding FDMT

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s FDMT Position: Q1 2025 in Review

Connor, Clark & Lunn Investment Management (CC&L) sold out of 4D Molecular Therapeutics (FDMT) in Q1 2025, closing a stake of 65,354 shares — an estimated $364K sold.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in FDMT in Q4 2022 and held it in 5 quarters. The position peaked at $1.07M in Q4 2022. 125 funds tracked by Wall St. Rank hold FDMT as of Q1 2025.

Connor, Clark & Lunn Investment Management (CC&L) reported no remaining 4D Molecular Therapeutics position as of Q1 2025 after selling out during the quarter.
Connor, Clark & Lunn Investment Management (CC&L) sold 65,354 4D Molecular Therapeutics shares in Q1 2025, an estimated $364K.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in 4D Molecular Therapeutics in Q4 2022 and held it in 5 quarters.
Connor, Clark & Lunn Investment Management (CC&L)'s 4D Molecular Therapeutics position peaked at $1.07M in Q4 2022.
125 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2025.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2025, filed 12 May 2025.